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Abstract
The charge of AAPM Task Group 113 is to provide guidance for the physics aspects
of clinical trials to minimize variability in planning and dose delivery for external
beam trials involving photons and electrons. Several studies have demonstrated the
importance of protocol compliance on patient outcome. Minimizing variability for
treatments at different centers improves the quality and efficiency of clinical trials.
Attention is focused on areas where variability can be minimized through standard-
ization of protocols and processes through all aspects of clinical trials. Recommenda-
tions are presented for clinical trial designers, physicists supporting clinical trials at
their individual clinics, quality assurance centers, and manufacturers.
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1 | ABOUT THIS EXECUTIVE SUMMARY
The full report of AAPM Task Group 113 on Guidance for the Phy-
sics Aspects of Clinical Trials is available at the AAPM Reports web-
site. This executive summary provides an overview of the major
headings of the full report. In addition, details were retained in this
report to highlight a few areas where there has been an evolution in
clinical trials. Appendices A–D include all of the TG113 recommen-
dations with the reference information contained in the full report.
2 | INTRODUCTION AND CHARGE OF THE
REPORT
There is growing evidence1–5 on the need for standardization of
treatment planning and delivery methods to ensure quality in clinical
trials to help support the investigation of new safe and effective
treatments and/or assessment methods in multi-institutional settings.
Such standardization will improve the consistency of the radiother-
apy received by patients and the radiotherapy data submitted for a
given clinical trial. These data are required to validate that all
patients in each arm of a given study received the therapy as
intended. Violating this assumption can jeopardize the validity of the
outcomes reported by the trial group.
A related consideration that affects overall quality is the ability of
those participating in clinical trials to create plans as part of their
standard clinical flow that are both compliant with protocol specifica-
tions and optimal. The importance of compliance in trials and the
impact on detecting changes in outcome have been demonstrated in
a number of trials,1–4,6 such as TROG 02.02 on advanced head and
neck cancer (Fig. 1), and in meta-analyses of other trials. When
designing a trial, the planning guidelines are set to be able to answer
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the clinical trial questions. However, there may be variation in plan-
ning methods, and a planner may not know when a better (such as
improved target coverage with reduced dose to normal tissues) plan
is reasonably achievable without real-time feedback during the plan-
ning process. Knowledge-based planning, where the achievable dose-
volume metrics from previous patients can used to predict each new
patient’s DVH, was shown to retrospectively identify plans which
were clinically acceptable but suboptimal in the context of the clinical
trial.7 For example, plan quality was analyzed for patients treated on
RTOG 0126 exploring the relationship between plan quality and rec-
tal toxicity. Suboptimal plans were identified by comparing predic-
tions for target and organ-at-risk doses to those that were submitted
as part of a trial for 219 IMRT patients. The library was created from
plans which were defined as the best from the protocol based on a
risk evaluation. This work highlights the challenge of using a series of
DVH points alone as the primary guidance to create a treatment plan.
There is a richness of information available when comparing a new
plan against a library of plans that have been previously determined
to be optimal and protocol compliant. Improved planning tools such
as those with knowledge-based planning have been needed for some
time to provide detailed feedback to institutions on whether or not
their treatment plans not only meet the dose-volume histogram
requirements but are also optimal for use in clinical trials. With
respect to quality assurance requirements, there are important ongo-
ing efforts toward global harmonization of quality assurance6 (such as
structure nomenclature addressed by AAPM Task Group (TG) 2638)
for radiation therapy clinical trials.
The charge of AAPM TG 113 is to:
(1) recommend physics practices for clinical trials involving external
photon and electron beam radiation therapy that ensure mini-
mum standards for data quality in clinical trials.
(2) identify opportunities to improve consistency in each part of
the planning and delivery process.
(3) provide guidance to QA organizations on how best to support
the spectrum of radiotherapy clinical trials, from those with
basic to advanced technology.
(4) provide suggestions regarding the credentialing requirements to
reduce potential inconsistencies in the radiotherapy process.
The use of protons or brachytherapy in clinical trials is outside of
the scope of this document. Throughout the report, recommenda-
tions are presented in each section for major areas of the process
from simulation through treatment delivery in the context of clinical
trials. The recommendations are organized by the categories of clini-
cal trial designers, physicists (at the local institution), quality assur-
ance (QA) centers, manufacturers, and advanced technology trials
and are also presented by category in Appendices A–D. The full
report includes information on restructuring of the clinical trials net-
work and associated QA centers funded by the NCI.
3 | THE ROLE OF THE PHYSICIST IN
CLINICAL TRIALS
Physicists play different roles with respect to clinical trials. At institu-
tional, national, and international levels, physicists may be lead or
co-investigators representing clinical and technical components. In
the context of clinical trial groups, physicists may lead or co-design a
clinical trial. For national trials supported at individual institutions,
physicists play a key role with physicians in ensuring protocol com-
pliance. Other perspectives include physicist roles in QA centers and
as employees of a manufacturer whose products are being used to
support clinical trials.
TG 113 considers the entire process designing a trial and its QA
through the activities of the local team from simulation to planning
and treatment delivery to improve the consistency for clinical trials,
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F I G . 1 . Peters et al. assessed the impact of protocol compliance for TROG 02.02 on advanced head and neck cancer and demonstrated an
impact on a) overall survival and b) time to locoregional failure as a function of the deviation status. (Figures 2 and 3 reprinted with permission
from Peters et al., JCO, 28: p. 2999.)
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AAPM task group reports are relevant to the work of TG 113. Figure 2
shows an overview of the major areas involved once a patient is
enrolled in a clinical trial. For each area, both sample relevant task
group reports and credentialing types are noted. Many of the
referenced task group reports are ones that are already relevant to the
practice of clinical medical physics in radiation therapy which then
have an impact on the treatment of patients enrolled in clinical trials.
Therefore, minimal additional references are made to task group
reports throughout this report.
4 | IMAGING
Image quality is paramount to many clinical trials for both target def-
inition and treatment assessment. This section makes recommenda-
tions to facilitate consistent and accurate volume definition for
clinical trials. Numerous collaborative efforts are focused on stan-
dardization of imaging, including quantitative applications. Formed in
2008, the Quantitative Imaging Biomarkers Alliance (QIBA) involves
drug and equipment companies and imaging societies and has a
charge to develop and advance standards for the use of volumetric
computerized tomography (CT), positron emission tomography (PET),
and magnetic resonance imaging (MRI) in clinical trials. QIBA has cre-
ated validated datasets including ones that can be used for evaluat-
ing lung nodules9 and phantom datasets that are used to validate
analytical tools such as dynamic contrast enhanced MRI.10 The Uni-
form Protocols for Imaging in Clinical Trials (UPICT) initiative has
created a protocol for trials involving imaging with FDG-PET/CT.11
Several groups within the AAPM are actively advancing the use of
quantitative imaging information, and guidance will continue to
evolve in this area.
Some clinical trials require credentialing or a central imaging
review by QA centers that have expertise in quantitative imaging,
such as IROC Ohio, IROC Philadelphia (DI), and IROC Rhode Island.
Credentialing may evaluate characteristics, such as image quality,
spatial integrity, and contrast; the requested characteristics depend-
ing on the role of imaging within a given trial. For example, consider-
ations with respect to understanding uncertainties in molecular
imaging have been described.12 More details regarding quantitative
imaging in clinical trials are presented in the full report.
5 | SEGMENTATION
Accurate segmentation is a critical task in clinical trials. Important
technical sources of variation in segmentation include variable win-
dow and level settings, the use and sensitivity of auto-segmenta-
tion algorithms to input parameters, and inappropriate margin
expansion algorithms. For example, inappropriate window and level
parameters can lead to significant bias and errors in volume defini-
tion with one study identifying factors leading to variations up to
42% by clinician which were reduced by using a standard proto-
col.13 Improvements in the consistency of contours are seen when
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F I G . 2 . This diagram shows the flow of the AAPM TG 113 report with respect to the patient treatment process (top row). Example
credentialing activities related to quality in clinical trials are shown in the middle row. The bottom row shows AAPM and other reports that are
related to the areas in the top row.
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protocol principal investigators. Training, such as via workshops or
webinars, should be provided to physicians and other personnel for
a given trial if there could be significant variability in the delin-
eation of structures.
For organs which will be evaluated with dose-volume histograms
(DVHs), the protocol should specify how much of the organ must be
contoured. For example, it may be appropriate to specify a region of
spinal cord to be contoured with respect to the superior and inferior
borders of the PTV. Structures with mean dose objectives should be
contoured in their entirety. For structures where the entirety may
not be included within the planning scan, the protocol should specify
dose limits in absolute (cc) instead of relative (%)volume.
It is crucial that protocol designers provide explicit guidance in
how structures are defined, especially when multiple structures are
involved. Significant differences have been shown in dosimetric
parameters for lung cancer for different definitions of normal lung,
the gross tumor volume, clinical target volume, internal target, or
planning target volume.14 Variability of such definitions in a clinical
trial would have a significantly detrimental impact on the ability of
the trial to resolve the study question. It may also lead to inconsis-
tency in the application of dose goals if the same dose goals are
used but with different definitions from one trial to another. There-
fore, definitions and dose goals across trials to the same body site
should be standardized as much as possible with the expectation of
evolution of care over time. In addition, the protocol should specify
any additional limits to doses to organs outside the treatment
field.15 A final critical concern is that some systems ignore the vol-
ume of an organ outside the dose calculation grid when reporting
dose-volume parameters. For such systems, the dose-grid should
cover the entire organ of interest so that derived dose-volume
parameters used for treatment planning represent the entire organ.
Additional details and recommendations regarding segmentation are
found in the full report.
6 | IMAGE REGISTRATION
Clinical studies that require multiple image datasets need to use
image registration software. When multiple image modalities are
used for treatment planning, the protocol designers should consider
providing specific recommendations for internal or external land-
marks that can validate the adequacy of the registration for treat-
ment planning.
If the accuracy of the image registration for each patient affects
the quality of the trial (such as in defining the target volume), the
protocol designers and QA centers should require credentialing of
the image registration software by using phantoms of known geome-
try and should follow the guidance of AAPM TG 132.16 The physi-
cian directive should specify the goals of the image registration, the
method and what anatomical region should be emphasized in the
registration.16
With respect to how image registration is used at the treatment
unit, the trials designers should determine if it is necessary to
distinguish between applications for target and normal tissue defini-
tion compared with daily online treatment guidance. Image registra-
tion considerations, which are described in the full report, may also
differ if there is a midcourse plan adaptation and dose accumulation
methods are utilized.17
7 | PATIENT AND TARGET POSITIONING
Patient and target positioning is affected by immobilization and the
frequency and type of image guidance used at the treatment unit.
The margins for treatment planning are affected, as well as the
achievable accuracy of image registration using multimodality imag-
ing scans which are used to design and assess patient treatments,
especially dose–response studies for clinical trials.
In the context of clinical trials, the type of recommended immo-
bilization described and/or required in a particular trial depends on
(a) the available and acceptable equipment in potentially accruing
clinics, (b) the accuracy required by the protocol; and (c) the fre-
quency and accuracy of the treatment guidance methods that may
be recommended during patient treatment. Trial designers should
determine if a given trial requires specific immobilization, such as for
stereotactic radiosurgery or stereotactic body radiation therapy.
More details regarding immobilization considerations are available in
the full report.
Protocols should be specific with respect to the type and fre-
quency of image guidance. The relationship between localization
methods and the appropriate PTV margin18 should be considered
in the design of all clinical trials. For example, a trial involving
treatment of breast cancer may involve weekly portal imaging,
whereas a trial involving SBRT may require daily volumetric imag-
ing. As described in the full report, the designers of clinical trials
should be specific with respect to the recommendations for intra-
and inter-treatment margins in a given trial for consistency and
reproducibility.
8 | MOTION ASSESSMENT AND
MANAGEMENT
For many treatment sites, physiological motion must be assessed to
determine if management of that motion is necessary for segmenta-
tion and treatment delivery. The AAPM Task Group 76 report, pub-
lished in 2006, provides guidance for considerations at simulation
and for treatment planning.19 Efforts are under way to update that
report with guidance needed today for clinic care and clinical trials.
In 2017, several members of the Medical Physics Committee of
NRG Oncology reviewed guidance in the context of stereotactic
body radiation therapy for thoracic and upper abdominal tumors and
made recommendations in the context of clinical trials.20 They
describe considerations regarding both motion assessment and
motion management.20 The full report of TG113 contains further
discussion of these considerations.
338 | MORAN ET AL.
9 | TREATMENT PLANNING
CONSIDERATIONS
With respect to treatment planning, there are considerations related
to the treatment planning system itself as well as the creation of
treatment plans for a given clinical trial. For example, more accurate
model-based algorithms rather than pencil beam algorithms should
be used for planning for patients in clinical trials. Recommendations
are also provided in the full report for clinical trial designers and
physicists at local institutions emphasizing tools that support
improved quality for clinical trials and that may improve efficiency as
well.
Protocol designers and manufacturers may be able to provide
templates and tools that can be used to support the uniform imple-
mentation of clinical trial guidelines. These tools may include struc-
ture templates that work on multiple vendor platforms such as
following the nomenclature recommendations of AAPM TG 263 and
advanced planning tools that aid in meeting the dosimetric require-
ments of a protocol. For example, a dosimetric model could be
developed for knowledge-based planning or a script could be created
with standard input such as the beam energy, beam arrangement,
and modality to best meet a given protocol.
Advances are being made in the use of automated tools for plan-
ning and for assessing the consistency of a treatment plan with
respect to previous clinical trials. This development has important
implications for clinical trials both for secondary analyses and for
more robustly assessing plan quality during the accrual phase of a
trial. The ability to improve plan quality using knowledge-based
methods was evaluated for RTOG 0126 where predictive DVHs
showed that further sparing of normal tissues was achievable with a
group of plans (Figure 3).7 Figure 3(e) demonstrates that plans which
were defined as “low quality” had significant improvements with
respect to the predicted rectal toxicity based on the calculated nor-
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F I G . 3 . Moore et al. retrospectively evaluated the impact of knowledge-based methods, such as calculation of a predicted DVH (pDVH), on
the overall IMRT plan quality for RTOG 0126 for prostate cancer and the resulting predicted grade 2 rectal normal tissue complication
probability (NTCP). (Figure courtesy of Moore et al.7).
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will be valuable both for the teams at the institution performing
treatment planning for protocol patients as well as for the analysis
of plan quality at the QA centers (https://www.nrgoncology.org/Scie
ntific-Program/Center-for-Innovation-in-Radiation-Oncology).
Additional considerations include considerations specific to adap-
tive therapy and re-irradiation. Emerging new technologies in radia-
tion treatment planning and image guidance will place additional
requirements on the capabilities of the TPS. Investigators and manu-
facturers are developing tools to better support adaptive therapy
such as deformable image registration and the creation of a model
based on the accumulated dose to a patient.21 Many of these con-
siderations are beneficial for patients who are retreated which may
also be a component of a clinical trial. Deformable registration and
fusion algorithms are currently being investigated and should ulti-
mately be included in the software tool set available at individual
institutions and at QA centers. These algorithms are an integral part
of accurately assessing and reporting the dose given to the patient
throughout the course of therapy. To fully appreciate the impact of
anatomical changes for case review in a clinical trial, the composite
delivered dose would be best, but if not available, multiple imaging
studies, their time sequences, and all treatment plans should be sub-
mitted to the QA center.
10 | TREATMENT DELIVERY
DOCUMENTATION
Treatment management systems permit verification that the correct
energy, beam modifiers, monitor units, treatment dates, and number
of fractions were used for individual patient treatments. A summary
of this information should be exportable in a standard format for a
clinical trial. This information is crucial because it has been shown
that some patients may have poorer outcomes as a result of missed
radiation therapy treatments.22 Missed treatments may also impact
the interpretation of the effectiveness of a clinical trial if not docu-
mented and considered. Clinical trial groups should consider the
implications of missed treatments and how best to collect the infor-
mation.
11 | QA CORE FUNCTIONS AND
INSTITUTIONAL PREPARATION
Credentialing for clinical trials is the performance and documentation
of specific processes by an institution and its team to demonstrate
their ability to accurately plan and treat patients for a particular pro-
tocol or treatment modality. In addition, a part of credentialing veri-
fies that the institution is capable of submitting the required
datasets to the QA center. The credentialing process is designed to
ensure that all participating institutions can faithfully apply the pro-
tocol guidelines and deliver comparable doses in a clinical trial. This
improves the ability to detect outcome differences within a given
trial.
Clinical trial groups face a challenge in determining the safest
way to adopt and incorporate new technologies in both existing and
newly developed clinical trials. When incorporating new or less uni-
formly applied technologies in clinical trials, the results of credential-
ing tests aid in discovering and correcting variable, outlier, or
noncompliant performance by participating institutions, and this
helps to lessen the variability in protocol performance across all
institutions. The test consist of a combination of questionnaires,
benchmark plans, dry-run digital data submissions, and phantom irra-
diations. If the institution passes the test, then it is approved for
enrollment of patients for the pertinent protocol and the specified
treatment modality. The full report has details regarding the purpose
and types of benchmarks, credentialing techniques, phantom consid-
erations, pretreatment, and on-treatment review.
A kick-off meeting is recommended with the appropriate
research staff, clinical trials coordinator, principal investigator, physi-
cist, dosimetrist, and a therapist before patients are enrolled on the
protocol. Examples of the types of things to discuss at a kick-off
meeting are included in the full report.
12 | SUMMARY
It has been shown that the quality and consistency of the trial
impacts patient outcomes.1–5 This report identifies physics and other
team member practices that specifically improve the treatment plan-
ning and delivery data for clinical trials. It provides benchmark and
other quality assurance recommendations for groups which design
and conduct clinical trials to minimize inconsistencies in the radio-
therapy processes and treatment. The details for each major section
along with recommendations are provided in the full report. The rec-
ommendations for the full report are presented in the appendices
for the clinical trial designers (Appendix A), physicists at individual
institutions (Appendix B), QA centers (Appendix C), and manufactur-
ers (Appendix D).
There are unique challenges posed by advanced technology trials
in a multi-institutional setting. To achieve the desired level of statis-
tical power in a clinical trial, the QA center must verify that the
technology is implemented uniformly in multiple settings. The QA
centers have had to adapt quickly as new technology becomes avail-
able and is implemented into clinical practice. Other guidance will
need to be developed as current advanced technologies mature and
other technologies develop.
With technological advancements, manufacturers play a role in
the development of improved technology and in providing updates
to software tools to enhance the conduct of clinical trials. Important
work has been ongoing in harmonization of credentialing for clinical
trials which the NCI has advocated along with other changes.23
Quality for NCI-funded clinical trials continues to be supported by
the IROC infrastructure. Finally, successful clinical trials involve a
partnership relationship among all of those involved.24 Improved
consistency in the design and performance of the physics aspects of
clinical trials will help ensure that the data are of high integrity and
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can be used to answer the clinical trial questions and ultimately
affect clinical practice.
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APPENDICES
These appendices consolidate the recommendations in the report for
ease of access by clinical trial designers, physicists, QA centers, and
manufacturers.
APPENDIX A. RECOMMENDATIONS FOR CLINICAL
TRIAL DESIGNERS
Imaging
a. Determine if imaging-specific credentialing is required through
a review by imaging experts (such as the imaging organizations
within IROC) and whether or not variability in techniques and/
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or variations in commercial scanner technology need to be
considered.
b. Design a standard operating procedure for imaging, incorporat-
ing expertise of imaging physicists/scientists where appropriate.
i. Specify the extent of anatomy to be imaged, including whole
organs when required for dose volume analyses
ii. Specify any timing requirements of the acquisition in relation
to treatment start for all imaging data for treatment planning
and assessment. Be explicit regarding patient preparations
for imaging.
iii. Keep image acquisition, reconstruction and analysis proce-
dures consistent when multiple imaging sessions for a
patient are required.
iv. Ensure consistent patient set-up and immobilization
between different imaging modalities and treatment (see
Sections 7 and 8) through credentialing of multi-modality
image registration.
v. Specify which contrast agents are permitted and provide
details on the timing and amount of the agent to be used.
vi. Provide guidelines on basic imaging parameters for trials
permitting different modalities such as MRI, MRS, and/or
PET/CT to account for the variability of different scan-
ners.
vii. Develop imaging benchmarks when modalities such as PET
and MRS are used to ensure that the department’s systems
for contouring are capable of representing that data ade-
quately in support of the clinical trial.
Segmentation
a. Specify window and level values, when appropriate, for consis-
tent visualization and segmentation.
b. Refer investigators to published consensus atlases for target and
organ at risk delineation as a reference when appropriate.
c. Provide training to physicians for a given trial if there could be
significant variability in the delineation of structures among
physicians.
d. Provide guidelines to physicians, physicists, and dosimetrists on
how to address imaging artifacts that interfere with target or
normal tissue segmentation (e.g. scatter from metal or the pres-
ence of contrast on a CT simulation scan).
e. For organs which will be evaluated with DVHs, the protocol
should specify how much of the organ must be contoured for
structures such as the spinal cord.
Image registration
a. For any applications of image registration in a trial, the protocol
designers should specify which methods are allowed (rigid only,
deformable), and any additional constraints.
b. Guidance should be provided about how the quality of an image
registration is judged which should distinguish between
applications for target and normal tissue definition compared to
daily online treatment guidance. This information should be con-
sidered when image registrations are evaluated as part of cre-
dentialing for a given trial.
Patient and target positioning
a. The clinical trial designers should survey the literature including
relevant AAPM Task Group reports to determine the type of
immobilization suitable to meet aims of the clinical trial.
b. Consult with physicist(s) at a lead institution and other possible
participating institutions to ensure that the proposed accuracy
limits are achievable at a number of centers.
c. Clearly specify which immobilization equipment is required for
the trial (where a preliminary assessment of equipment availabil-
ity in the community could be done via the IROC Houston facil-
ity questionnaire if needed) or if certain types of equipment are
not permitted.
d. Use the most up-to-date terminology to specify definitions of
target volumes in the trial design (e.g. ICRU #83 at time of pub-
lication).
e. Review data in the literature to define acceptable PTV margins
related to the technology used for simulation (such as 4DCT)
and the frequency and type of imaging for the anatomical site.
f. Provide explicit guidance on the contouring of targets and nec-
essary expansions.
g. If a protocol requires an evaluation of target margins midtreat-
ment, the clinical trial designers should specify the frequency
and methods of evaluation in the clinical trial design. For exam-
ple, how to address changes in tumor physiology and/or shape
such as changes to targets in the lung or head and neck region
due to shrinkage or growth of the tumor.
Motion assessment and management
a. For relevant body sites, specify that the degree of target motion
should be assessed at the time of simulation. For treatment sites
where the impact of motion can be crucial, it is recommended
that QA centers develop guidance, with respect to the accept-
able imaging techniques to assess motion, documentation of that
motion for a given patient, and how the information should be
incorporated for creating target volumes.
b. Incorporate guidance on motion management techniques in
which the range of motion is greater than published limits (or
significant normal tissue sparing can be achieved through their
use). For trials when target motion may be ≥5 mm and delivery
of a high daily dose (e.g. SBRT), institutions should be required
to document the assessment and follow formal guidance such as
that provided by AAPM TG 7619 or other organizations such as
NRG20 to ensure motion assessment and management informa-
tion is accurately captured for patients enrolled on the trial.
c. For protocols involving monitoring of intra-fraction motion, pro-
vide information regarding the acceptable technologies for
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monitoring and the thresholds for evaluation. Information should
be provided as to whether intra-fraction monitoring is required
and the acceptable methods.
Treatment planning considerations
a. Specify standard structure names that must be used for the clin-
ical trial (follow consensus guidance when available) such as pro-
vided by AAPM TG 263 or other appropriate ontologies.
b. Use published information on normal tissue limits such as
through consensus efforts as appropriate when specifying the
limits to normal tissues.
c. For organs which will be evaluated with DVHs, the protocol
should specify how much of the organ must be contoured for
structures such as the spinal cord.
d. Specify spatial resolution requirements for dose and DVH calcu-
lations that are commensurate with target and organ-at-risk
(OAR) sizes.
e. Specify the use of 3-D treatment planning for all clinical trials
(excluding special procedures such as total body irradiation or
total skin electron treatments).
f. Require the use of more accurate algorithms (such as convolu-
tion/superposition, Monte Carlo) for trials where tissue hetero-
geneities may be significant.
g. Develop credentialing approaches for new applications of the
TPS, such as biological treatment planning.25 Credentialing may
include intercomparison of results using standardized datasets.
h. Specify the dose-volume constraints for organs-at-risk and con-
sider any special concerns such as the buildup region or struc-
tures outside the treatment area.
i. Specify the minimization of the integral dose or total dose to
other normal tissues that may not be contoured in trials which
allow the use of dose optimization techniques.
Treatment planning delivery documentation
a. Determine which aspects of the treatment history should be
required as part of the data submission
b. Require a record of missed treatments as part of the data sub-
mission.
QA core functions and institutional preparation
a. For credentialing, explicitly state which structures must be delin-
eated by a physician rather than other personnel.
b. Work with QA center staff to determine the type of credential-
ing and if existing benchmarks or other credentialing tests are
appropriate before designing new tests.
c. Require a credentialing process with pre- or on-treatment
review for at least the first few cases and perhaps for all cases
prior to treatment for trials that are dependent on consistent
contouring of target and normal structures, adherence to strict
margin expansions, dose-volume constraints, and novel treat-
ment techniques.
d. Require credentialing of technologies which may be susceptible
to significant inter-institutional variability.
e. Confirm with physicist stakeholders (such as the NRGMedical Phy-
sics group and the AAPMWork Group on Clinical Trials), physicians
and administrators when necessary to assess there are enough cen-
ters with adequate equipment and personnel available to meet the
specifications, guidelines, benchmarks, and credentialing require-
ments (by the center) in a timely manner [estimate time of needed
training(s)].
f. Require QA centers to confirm that the submitted treatment
plan of a benchmark irradiation meets the specified requirements
for the phantom plan, not only that the measurements and cal-
culations are in agreement.
g. For applicable treatment sites, require a benchmark test that
assesses the accuracy of image fusion, IGRT, or other methods
critical to the outcome of the trial performed by the institutional
personnel routinely planning and treating patients in the clinical
trial.
h. The protocol should specify who reviews the case (QA center
staff, study principal investigators and co-investigators, or other
designated reviewers), the number of cases from each center to
be reviewed (e.g. the first 2 patients enrolled from a given cen-
ter or based on compliance), the type and timing of the review,
and whether or not the credentialing should be for each partici-
pating physician or the institution as a whole.
APPENDIX B. PHYSICISTS AT THE LOCAL INSTITUTION
Imaging
a. Train and work with the appropriate personnel to implement the
protocol-specified imaging standard operating procedures for
image acquisition, reconstruction, processing, and analysis.
b. Review patient imaging scans regularly to ensure compliance to
the standard operating procedure.
c. Consider the utilization of immobilization and setup methods
and devices that are compatible with all imaging modalities used
in the trial to reproduce the setup for the treatment planning
CT.
Image Registration
a. Evaluate the ability of the institution to follow protocol guideli-
nes for segmentation and image registration.
b. Follow recommendations of AAPM TG 132 with respect to
image registration.16
c. Adjust monitors for adequate resolution and properly calibrate
for contrast and brightness to ensure consistency in target delin-
eation.26 Note minimum settings in the standard operating pro-
cedure.
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Patient and target positioning
a. Determine that the institution’s immobilization equipment is
appropriate for the clinical trial before IRB submission.
b. Ensure consistency of equipment for planning and treatment, for
example, flat table tops for diagnostic scanners, use of compatible
immobilization equipment for imaging scans when possible.
c. Confirm the accuracy of the immobilization method used in the
clinic for the protocol.
d. Ensure personnel are adequately trained to support the process.
e. For each protocol, understand how target margins are specified
and make sure the margins are reasonable for the department’s
imaging, immobilization, planning, delivery, and treatment guid-
ance process for the patients enrolled on the trial.
f. For each protocol, monitor the effectiveness of the patient local-
ization method for the patients enrolled on the trial.
Motion assessment and management
a. Confirm that the motion assessment and management guidance
specified in the protocol is followed whenever the range of
motion meets published guidance limits.
b. Ensure that the contoured IGTV is reasonable considering the
measured motion for a given protocol patient.
Treatment planning considerations
a. Ensure that the TPS is capable of meeting protocol requirements
by:
i. Use of a model-based algorithm such as convolution/super-
position, Monte Carlo, or deterministic methods
ii. Accurate modeling of beams and output factors, especially
for small fields and IMRT techniques
iii. Validating the dose-volume histogram and analysis algo-
rithms
b. Ensure that 3D volumetric information can be exported to the
Clinical Trial QA Center in DICOM-RT format.
c. Implement templates in your treatment planning system to use
the standard names for targets and structures as specified by
the clinical trial designers.
d. Coordinate an end-to-end dry run of the protocol at his or
her center on one of their patient dataset(s). (Note that this
requires support from the department’s administration for this
valuable effort.)
e. Determine the degree of attenuation by immobilization equip-
ment and determine whether the attenuation should be
accounted for in monitor units (MU) calculations.
QA core functions and institutional preparation
a. Repeat the credentialing benchmark if a major change is made
that may affect the quality in the clinical trial. Changes
such as to the dose calculation algorithm may only require
a resubmission of calculation data results rather than a
re-irradiation.
b. Read the protocol and become familiar with the protocol guide-
lines and credentialing requirements to serve as the institutional
expert on the planning and delivery details of each protocol that
involves radiotherapy.
c. Complete the Credentialing Status Inquiry (CSI) form and
request the credentialing phantom for a particular trial, if
needed. Treat the phantom as a patient, including involvement
of the appropriate personnel. Return the phantom to the QA
center in a timely manner.
d. Work with the institutional team, including the physician, to
ensure a kick-off meeting for the protocol and to create proto-
col-specific simulation and planning directives to ensure protocol
compliance.
e. Coordinate, develop, and perform an end-to-end test for a given
protocol where each team member does his or her part to test
drive and make corrections to the process before the first proto-
col patient is enrolled.
APPENDIX C. RECOMMENDATIONS FOR QA CENTERS
Imaging
a. Specify if an existing imaging benchmark would be beneficial for
ensuring that enrolling institutions would be able to acquire
scans of the appropriate quality to support the trial.
Image registration
a. Develop imaging benchmarks as needed including when modali-
ties such as PET and MRS are used to ensure that the depart-
ment’s systems for contouring are capable of representing that
data adequately in support of the clinical trial.
b. Develop credentialing methods incorporating deformable image
registration following the recommendations of AAPM TG 132.16
Patient and target positioning
a. Confirm that the precision of commercial immobilization sys-
tems and field experiences indicate that the proposed tech-
niques realistically can meet the accuracy requested in the
protocol.
b. Ensure the appropriateness of the margin for a given trial.
c. Determine credentialing methods for new techniques such as
those requiring intra-fraction monitoring.
Motion assessment and management
a. Determine if a motion benchmark is required in support of
specific trials with motion considerations using existing bench-
marks where reasonable.
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Treatment planning considerations
a. Enable as much automation of data submission as possible.
b. Continue validation and cross-comparison of the performance of
different dose algorithms with other QA centers and revise
requirements as appropriate.
c. Work with manufacturers to design interfaces that can be
customized for electronic submission of all necessary proto-
col data.
d. Provide the clinical trial groups with a template of standard tar-
get and structure names so that the clinical trial designers use
consistent names across clinical protocols. Once available, the
nomenclature of AAPM TG 263 should be followed.
e. Develop mechanisms to share scripts or other tools (such as
Excel Sheets with Macros enabled) to aid the institutional teams
in assessing whether or not protocol guidelines are met prior to
submission to the QA center. Tools could potentially be devel-
oped on multiple TPS platforms.
QA core functions and institutional preparation
a. Regarding data format:
i. Have a methodology for anonymization of patient data if
appropriate for a benchmark planning study. For example,
TRIAD (NRG Oncology) includes an anonymization function.
ii. When needed for a study, image format should be DICOM
or DICOM RT (as appropriate) for CT, MR, PET, portal, sim-
ulator, and DRR images.
iii. When needed for a study, structure set, plan and dose files
should be in DICOM RT format.
iv. Supplemental data that needs to be submitted to QA cen-
ters should be able to be electronically submitted.
b. For new protocols, determine if an existing benchmark would
meet the testing needs of the clinical trial.
c. Develop benchmarks which are applicable across cooperative
groups.
d. Annually review facility questionnaires for all institutions par-
ticipating in clinical trials.
e. Determine when re-credentialing is necessary.
f. Provide appropriate benchmark phantoms for each trial that
requires them, as resources permit.Existing phantoms should be
assessed for suitability before new ones are made.
g. Determine benchmark acceptability based on reasonable clinical
practice for the radiation treatment convolved with the 90%
confidence limit of the dose measurements by the QA center.
h. Make information available to team members at an institution
to determine eligibility for a given trial based on past creden-
tialing efforts.
i. When new planning and delivery techniques are introduced,
evaluate the consistency with a subset of centers. This informa-
tion should aid in assessing the appropriateness and need of a
phantom irradiation.
j. When large variability exists in benchmark results, work with key
stakeholders to identify causes and methods to minimize dosi-
metric discrepancies. This may include working with physicists at
local institutions as well as with manufacturer representatives.
k. Develop with imaging experts a suite of benchmark phantoms
and a robust program for image acquisition QA with different
systems.
APPENDIX D. RECOMMENDATIONS FOR
MANUFACTURERS
Imaging
a. For a given registration, develop methods to capture the primary
goals of the image registration (e.g. target evaluation or organ-
at-risk) and the goodness of the registration (see TG132 recom-
mendations)16
b. In image registration software, provide the ability to export neces-
sary data for QA centers to be able to assess the quality of a regis-
tration (quantitative and qualitative) and export the needed
information for straightforward review by those credentialing for
clinical trials and investigators for patients enrolled in clinical trials.
Patient and target positioning
a. Make immobilization devices that enhance reproducibility of
patient setup over time so serial images can be used for quanti-
tative treatment assessment and subsequent treatment planning.
b. Incorporate interchangeable fiducials in the immobilization
devices to facilitate merging the scans from two or more types
of instruments, such as MRI, CT, and PET.
c. Develop tools to quantitatively review localization images with
field outline and anatomy contours exported from the treatment
management system.
d. Develop tools to quantitatively monitor daily setup correction
trends for patient positioning such as from on-board imaging or
other methods.
Motion assessment and management
a. Provide online 4D tools such as 4D CBCT capability at the
treatment machine to support protocol motion management
requirements.
b. Provide tools to document range of motion on platforms for dif-
ferent imaging platforms.
Treatment planning considerations
a. Include DICOM-RT export in the base purchase of a TPS rather
than an add-on option with the ability to export anonymized
cases to the QA centers (including image datasets, plans, struc-
tures, and dose).
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b. Provide standard target and structure names as provided by the
QA centers or allow upload of files with the names of the struc-
tures (as defined in AAPM TG 263)
c. Enable use of protocol-specific scripts including standard target
and structure names (AAPM TG 263).
d. Create interfaces that import the necessary standard names,
beam arrangement (if appropriate), and other information for
treatment planning.
e. Create the appropriate software to allow automatic anonymiza-
tion with coded ID labels of patients and plans.
f. Develop and make available a straightforward export of informa-
tion to QA centers
g. Make treatment planning systems IHE-RO compliant
h. Enable tools or scripts that can be shared and then used at the
local institution to assess protocol compliance are invaluable.
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